Difference between revisions of "Chlorambucil (Leukeran)"

Revision as of 15:52, 17 June 2022

General information

Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is established

Follicular lymphoma

Diseases for which it is used

Diseases for which is was used

Patient drug information

History of changes in FDA indication

3/18/1957: Initial FDA approval
11/13/2003 (earliest label available on Drugs@FDA): indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Also known as

Brand names: Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan

References

[insert-1] 1.0 ^1.1 ^1.2 Chlorambucil (Leukeran) package insert

[2] Chlorambucil (Leukeran) package insert (locally hosted backup)

[3] Chlorambucil (Leukeran) patient drug information (Chemocare)

[4] Chlorambucil (Leukeran) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 29: / Line 29: @@
 ==History of changes in FDA indication==
 *3/18/1957: Initial FDA approval
-*11/13/2003: (earliest label available on Drugs@FDA) indicated in the treatment of [[Chronic lymphocytic leukemia|chronic lymphatic (lymphocytic) leukemia]], [[:Category:Lymphomas|malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease]]. It is not curative in any of these disorders but may produce clinically useful palliation.
+*11/13/2003 (earliest label available on Drugs@FDA): indicated in the treatment of [[Chronic lymphocytic leukemia|chronic lymphatic (lymphocytic) leukemia]], [[:Category:Lymphomas|malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease]]. It is not curative in any of these disorders but may produce clinically useful palliation.
 ==Also known as==